Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans

Molecular Medicine Reports

Volumn 8, Issue 2, 2013, Pages 579-584

  You, Jeong Soon ^a   Ji, Hye In ^b   Chang, Kyung Ja ^a   Yoo, Myung Chul ^b   Yang, Hyung In ^b   Jeong, In Kyung ^b   Kim, Kyoung Soo ^b  

^a Inha University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Adiponectin; Exercise induced fat mass loss; Leptin; Obesity; Osteopontin

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; OSTEOPONTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EXERCISE; FEMALE; HUMAN; HUMAN EXPERIMENT; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADIPOSE TISSUE; ADIPOSITY; ADULT; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; EXERCISE; FEMALE; HUMANS; LEPTIN; LIPIDS; MUSCLE, SKELETAL; OBESITY; ORGAN SIZE; OSTEOPONTIN; TIME FACTORS; YOUNG ADULT;

EID: 84879923482     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1522     Document Type: Article

References (36)

1. Harford KA, Reynolds CM, McGillicuddy FC and Roche HM: Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc 70: 408-417, 2011.
2. Morimoto J, Kon S, Matsui Y and Uede T: Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 11: 494-505, 2010.
3. Nomiyama T, Perez-Tilve D, Ogawa D, et al: Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117: 2877-2888, 2007.
4. Kiefer FW, Zeyda M, Todoric J, et al: Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149: 1350-1357, 2008.
5. Gómez-Ambrosi J, Catalán V, Ramírez B, et al: Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92: 3719-3727, 2007.
6. Xu G, Sun W, He D, et al: Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32: 410-416, 2005.
7. Braitch M and Constantinescu CS: The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm Allergy Drug Targets 9: 249-256, 2010.
8. Frenzel DF and Weiss JM: Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol 7: 93-109, 2011.
9. Waller AH, Sanchez-Ross M, Kaluski E and Klapholz M: Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev 18: 125-131, 2010.
10. Naldini A, Leali D, Pucci A, et al: Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 177: 4267-4270, 2006.
11. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006.
12. Kiefer FW, Neschen S, Pfau B, et al: Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 54: 2132-2142, 2011.
13. Zeyda M, Gollinger K, Todoric J, et al: Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology 152: 2219-2227, 2011.
14. Komorowski J, Jankiewicz-Wika J, Kolomecki K, et al: Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine 55: 56-61, 2011.
15. Schaller G, Aso Y, Schernthaner GH, et al: Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg 19: 351-356, 2009.
16. Shevde LA, Das S, Clark DW and Samant RS: Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 10: 71-81, 2010.
17. Giachelli CM and Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19: 615-622, 2000.
18. Reinholt FP, Hultenby K, Oldberg A and Heinegård D: Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 87: 4473-4475, 1990.
19. Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
20. Sowers MR and Karvonen-Gutierrez CA: The evolving role of obesity in knee osteoarthritis. Curr Opin Rheumatol 22: 533-537, 2011.
21. Shehzad A, Ha T, Subhan F and Lee YS: New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity- related metabolic diseases. Eur J Nutr 50: 151-161, 2011.
22. Trayhurn P and Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92: 347-355, 2004.
23. Wärnberg J, Cunningham K, Romeo J and Marcos A: Physical activity, exercise and low-grade systemic inflammation. Proc Nutr Soc 69: 400-406, 2010.
24. Gleeson M, Bishop NC, Stensel DJ, et al: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11: 607-615, 2011.
25. Klempel MC and Varady KA: Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. Nutr Rev 69: 145-154, 2011.
26. Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ and Burrell MA: The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280: E827-E847, 2001.
27. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun 31: 560-564, 2012.
28. Shehzad A, Iqbal W, Shehzad O and Lee YS: Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens) 11: 8-20, 2012.
29. Guerre-Millo M: Adiponectin: an update. Diabetes Metab 34: 12-18, 2008.
30. Riedl M, Vila G, Maier C, et al: Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab 93: 2307-2312, 2008.
31. Humphries B, Fenning A, Dugan E, et al: Whole-body vibration effects on bone mineral density in women with or without resistance training. Aviat Space Environ Med 80: 1025-1031, 2009.
32. Smith EL and Gilligan C: Physical activity effects on bone metabolism. Calcif Tissue Int 49 (Suppl): S50-S54, 1991.
33. Reis CE, Bressan J and Alfenas RC: Effect of the diet components on adiponectin levels. Nutr Hosp 25: 881-888, 2010.
34. Tamura A, Shingai M, Aso N, et al: Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 67: 742-744, 2003.
35. Oh KW, Lee WY, Rhee EJ, et al: The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 63: 131-138, 2005.
36. Villareal DT, Fontana L, Weiss EP, et al: Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med 166: 2502-2510, 2006.